This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

MannKind Soars 100%+ on Buyout Chatter, Coming FDA Decision: StockTwits

NEW YORK (TheStreet) -- MannKind's (MNKD) stock is soaring ahead of the FDA's July 15 decision on whether to approve the biotech company's inhaled insulin drug Afrezza.The stock was up more than 7% today to $10.19 as of 11:45 a.m. Wednesday.

But even the biotech bulls on are uneasy buying in to a company with a near $3.8 billion market cap and no revenue.

$MNKD added more shares this morning at $9.99. Hope this wasn't a dumb move but riding this donkey to July 15!

? Huy Thai (@thai0911) Jun. 4 at 10:24 AM

Still, sentiment on the stock is 96% bullish according to StockTwits analytics.

The reason is that the Afrezza approval is believed to be a foregone conclusion. In April, an FDA panel overwhelmingly recommended the drug to treat patients with either type of diabetes, despite some concerns about lung complications from inhaling insulin.

MannKind shares have climbed 151% since April 1, the day before the Endocrinologic and Metabolic Drug Advisory Committee announced its recommendation.

$MNKD if every day goes up with 50 cents, we'll end up around 40 till approval day..

? Ozgur (@Kafkafnl) Jun. 4 at 10:49 AM

What gives investors some pause about buying in at current levels isn't the risk that the drug will be rejected, but whether the company can successfully market and sell the drug quickly enough to justify its valuation. If there are any signs that the company, while capable of developing a blockbuster drug, can't sell it effectively, then shareholders could sell.

$MNKD Don't want to stop the bull rush but this stock IS up like 50% in past month with approval anticipation. How higher can it go post?

? KJ (@saskatrade) Jun. 4 at 10:13 AM

Of course, many on StockTwits believe that MannKind will never have to really sell Afrezza. They are banking that the company will be purchased by a pharmaceutical giant shortly after the drug is approved.

So who might buy MannKind?

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
MRK $55.08 0.00%
MNKD $1.48 0.00%
AAPL $95.18 0.00%
FB $117.43 0.00%
GOOG $692.36 0.00%


Chart of I:DJI
DOW 17,750.91 -140.25 -0.78%
S&P 500 2,063.37 -18.06 -0.87%
NASDAQ 4,763.2240 -54.37 -1.13%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs